Real World Data of the Impact of First Cycle Daratumumab on Multiple Myeloma and AL Amyloidosis Services

British Journal of Haematology- United Kingdom

doi 10.1111/bjh.14897

Full Text

Abstract

Available in

Categories

Hematology

Date

Authors

Publisher

Wiley

Related search

Single Agent Daratumumab in Advanced Multiple Myeloma Possesses Significant Efficacy Even in an Unselected "Real-World" Population

Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia
BiochemistryMedicineGeneticsMolecular Biology
2019English

Daratumumab Proves Safe and Highly Effective in AL Amyloidosis

British Journal of Haematology
Hematology
2018English

Daratumumab in Untreated Newly Diagnosed Multiple Myeloma

Therapeutic Advances in Hematology
Hematology
2019English

Impact of the Affordability of Novel Agents in Patients With Multiple Myeloma: Real-World Data of Current Clinical Practice in Mexico

Cancer
Cancer ResearchOncology
2018English

The Occurrence of AL Amyloidosis (Light-Chain Amyloidosis) in Patients With Multiple Myeloma in Lower Silesia Region, Poland

Advances in Clinical and Experimental Medicine
BiochemistryMedicineGeneticsMolecular Biology
2014English

Multiple Myeloma With Primary Amyloidosis

Journal of the Royal Society of Medicine
Medicine
1997English

Multiple Myeloma-Associated AL Amyloidosis: Is a Distinctive Therapeutic Approach Warranted?

Bone Marrow Transplantation
TransplantationHematology
2006English

Real-World Data on Safety and Efficacy of Venetoclax-Based Regimens in Relapsed/Refractory T(11;14) Multiple Myeloma

British Journal of Haematology
Hematology
2020English

Split First Dose Administration of Intravenous Daratumumab for the Treatment of Multiple Myeloma (MM): Clinical and Population Pharmacokinetic Analyses

Advances in Therapy
MedicinePharmacology
2020English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2026 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy